ストックスクリーナーアプリを入手
1.67
1.18%
-0.02
アフターアワーズ：
1.67
前日終値:
$1.69
開ける：
$1.7
24時間の取引高:
456.96K
Relative Volume:
0.45
時価総額：
$302.40M
収益：
$109.16M
当期純損益:
$-107.78M
株価収益率:
-1.5095
EPS:
-1.1063
ネットキャッシュフロー:
$-95.45M
1週間 パフォーマンス:
-10.22%
1か月 パフォーマンス:
-23.04%
6か月 パフォーマンス:
-19.32%
1年 パフォーマンス:
+242.42%
1日の値動き範囲:
$1.63
$1.78
1週間の範囲:
$1.63
$1.94
52週間の値動き範囲:
$0.435
$3.04
Century Therapeutics Inc Stock (IPSC) Company Profile
名前
Century Therapeutics Inc
セクター
電話
215-981-4000
住所
25 N 38TH STREET, 11TH FLOOR, PHILADELPHIA
Compare IPSC vs VRTX, REGN, MRNA, ARGX, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IPSC
Century Therapeutics Inc
|
1.67 | 302.40M | 109.16M | -107.78M | -95.45M | -1.1063 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Century Therapeutics Inc Stock (IPSC) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-25 | 開始されました | TD Cowen | Buy |
| 2024-08-08 | 開始されました | Rodman & Renshaw | Buy |
| 2023-08-28 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2022-12-27 | 開始されました | Chardan Capital Markets | Buy |
| 2022-10-31 | 開始されました | Guggenheim | Buy |
| 2022-10-10 | 開始されました | Canaccord Genuity | Buy |
| 2022-05-23 | 開始されました | H.C. Wainwright | Buy |
| 2022-05-12 | 開始されました | William Blair | Mkt Perform |
| 2021-07-13 | 開始されました | BofA Securities | Buy |
| 2021-07-13 | 開始されました | JP Morgan | Overweight |
| 2021-07-13 | 開始されました | Piper Sandler | Overweight |
すべてを表示
Century Therapeutics Inc (IPSC) 最新ニュース
Form 144 Century Therapeutics For: 25 September By Investing.com - Investing.com Canada
Century Therapeutics stock falls 6.88 percent as milestones approach - AD HOC NEWS
Century Therapeutics, Inc.(NasdaqCM: IPSC) added to S&P Global BMI Index - marketscreener.com
Century Therapeutics stock extends strong run as IPSC jumps over 700 percent in 12 months - AD HOC NEWS
Century Therapeutics stock falls as IPSC trades near 52-week low - AD HOC NEWS
Russotti Gregory Disposes 2,587 Shares of Century Therapeutics (NASDAQ: IPSC) at $1.93 Each - Kalkine Media
Century Therapeutics SVP Douglas Carr sells $3,199 in shares By Investing.com - Investing.com South Africa
Century Therapeutics SVP Douglas Carr sells $3,199 in shares - Investing.com
Century Therapeutics (IPSC) exec sale covers RSU taxes - Stock Titan
Century Therapeutics (IPSC) CEO holds 3,633,839 shares after tax move - Stock Titan
Century Therapeutics (IPSC) insider sale only covers tax withholding - Stock Titan
Century Therapeutics (NASDAQ: IPSC) officer intends $4,994 sale of stock - Stock Titan
Century Therapeutics (NASDAQ: IPSC) officer lines up 1,658-share stock sale - Stock Titan
LRMR News | LARIMAR THERAPEUTICS INC (NASDAQ:LRMR) - ChartMill
Century Therapeutics (IPSC) awards 148,000 options vesting over 3 years - Stock Titan
Century Therapeutics Adds Director, Advances Cell Therapy Pipeline - The Globe and Mail
Century Therapeutics' SVP Finance Carr Douglas Sells 254 Shares at $2.05 Each (NASDAQ: IPSC) - Kalkine Media
Century Therapeutics (NASDAQ: IPSC) Insider Russotti Gregory Sells 534 Shares, Retains 511,785 Shares - Kalkine Media
Century Therapeutics SVP sells $520 in stock for tax withholding By Investing.com - Investing.com Australia
Century Therapeutics appoints iECURE CEO Joseph Truitt to board - Bitget
Century Therapeutics Adds Joseph Truitt to Board of Directors - Minichart
Century Therapeutics CEO Brent Pfeiffenberger Withholds Shares for Tax on RSU Vesting - Kalkine Media
Century Therapeutics CTO Gregory Russotti Executes Automatic Sale of 534 Shares for Tax Withholding - Kalkine Media
Century Therapeutics appoints Joseph Truitt to board By Investing.com - Investing.com Nigeria
Century Therapeutics SVP sells $520 in stock for tax withholding - Investing.com
Century Therapeutics (IPSC) CEO shares withheld for taxes on RSU vesting - Stock Titan
Tax-withholding sale trims Century Therapeutics (NASDAQ: IPSC) insider by 534 shares - Stock Titan
Automatic tax sale leaves Century Therapeutics (NASDAQ: IPSC) SVP with 504,565 shares - Stock Titan
Century Therapeutics adds director, sets 2026 trial timelines - Stock Titan
Century Therapeutics appoints Joseph Truitt to board - Investing.com
Century Therapeutics Appoints Joseph Truitt to Board of Directors - Yahoo Finance UK
Century Therapeutics (NASDAQ: IPSC) officer plans stock sale partly to cover taxes - Stock Titan
Century (IPSC) Range: Rises 2.66% to $2.12 in the Latest Reading; Price Setup: the Supplied Trading Band Runs From $2.01 to $2.23 in the Latest SessionDynamic Hedging - careplusvn.com
Century (IPSC) Earnings Reading: EPS Beats Its Estimate at the Close; Share Move: The Stock Records a 4.27% Decrease in Latest TradingGuidance vs Actual - vinanet.vn
Century Targets FDA Filing for Diabetes Cell Therapy - MyChesCo
Century Therapeutics CEO Brent Pfeiffenberger Completes RSU Tax Withholding Share Transaction - Kalkine Media
Century Therapeutics (IPSC) CEO stock withheld for taxes - Stock Titan
Mizuho Securities Maintains Century Therapeutics(IPSC.US) With Buy Rating, Maintains Target Price $8 - Moomoo
HC Wainwright Issues Pessimistic Forecast for IPSC Earnings - MarketBeat
IPSC Q1 2026 Earnings: Narrower-Than-Expected Loss Yields 31.76% EPS SurpriseMid-Term Outlook - vinanet.vn
TD Cowen Maintains Century Therapeutics(IPSC.US) With Buy Rating - Moomoo
Century Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Century Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Century Therapeutics (NASDAQ:IPSC) Issues Quarterly Earnings Results - MarketBeat
Century Therapeutics Announces Q2 2026 Financial Results and Updates Investor Presentation in 8-K Filing - Kalkine Media
Form 8K Century Therapeutics Inc For: 12 August - Investing.com India
Century Therapeutics Reports Q2 Results, Pipeline Advancements - TipRanks
Form 8K Century Therapeutics Inc For: 12 August By Investing.com - Investing.com Canada
Century Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates - The Manila Times
Century Therapeutics posts $34.6 million Q2 loss as cash runway reaches 2029 - Quiver Quantitative
Century Therapeutics 2Q 2026: Revenue $0 EPS $(0.17) — 10-Q Summary - TradingView
Century Therapeutics Inc (IPSC) 財務データ
収益
当期純利益
現金流量
EPS
3.06%
2.55%
大文字化:
|
ボリューム (24 時間):